Nantahala Capital Management, LLC

Position in SVRA — Savara Inc

CIK 1472322 New Canaan, CT

Position in SVRA

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$40,102,515

-$4,186,526 QoQ

Shares Held

7,344,783

0.0% QoQ

Ownership

3.58%

of shares outstanding

% of Portfolio

2.52%

of 13F equity value

Holder Rank

#10

of 184 holders

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Nantahala Capital Management, LLC holds $574,927,961 across 52 Biotechnology names. SVRA ranks #2 (7.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	SLNO	Soleno Therapeutics Inc	1,744,124	$58,393,271
2	SVRA	Savara Inc This page	7,344,783	$40,102,515
3	TNGX	Tango Therapeutics, Inc.	1,250,452	$26,159,455
4	LBRX	Lb Pharmaceuticals Inc	1,052,894	$25,964,366
5	MLYS	Mineralys Therapeutics, Inc.	895,481	$24,258,580
6	ZVRA	Zevra Therapeutics, Inc.	2,521,936	$23,504,443
7	FULC	Fulcrum Therapeutics, Inc.	3,050,040	$23,393,806
8	ABEO	Abeona Therapeutics Inc.	5,013,052	$22,458,472

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$40,102,515	7,344,783	0.0%	Shares	Sole	2026-05-15
2025-12-31	$44,289,041	7,344,783	-16.3%	Shares	Sole	2026-02-13
2025-09-30	$31,328,088	8,775,375	+5.4%	Shares	Sole	2025-11-14
2025-06-30	$18,981,855	8,325,375	+3.1%	Shares	Sole	2025-08-14
2025-03-31	$22,368,788	8,075,375	+7.3%	Shares	Sole	2025-05-15
2024-12-31	$23,102,545	7,525,259	+45.2%	Shares	Sole	2025-02-14
2024-09-30	$21,967,232	5,180,951	0.0%	Shares	Sole	2024-11-14
2024-06-30	$20,879,232	5,180,951	+198.2%	Shares	Sole	2024-08-20
2024-03-31	$8,652,301	1,737,410	+75.9%	Shares	Sole	2024-05-15
2023-12-31	$4,643,144	987,903	-5.0%	Shares	Sole	2024-02-15
2023-09-30	$3,928,795	1,039,364	—	Shares	Sole	2023-11-14
No filing history on record for this holder in this stock.